Methotrexate Intravitreal Injection During Rhegmatogenous Retinal Detachment Repair Surgery to Prevent Proliferative Vitreoretinopathy | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2024, Issue 5, May 2024 | ||||
| DOI: 10.58675/2682-339X.2456 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Hassan Hegazy1; Mostafa Hussein1; mahmoud deif2 | ||||
| 1Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||||
| 2Ophthalmology, Research Institute of Ophthalmology, Cairo, Egypt | ||||
| Abstract | ||||
| Background and Purpose: The only therapy for Proliferative vitreoretinopathy (PVR) is surgical, and the functional prognosis is poor. Methotrexate (MTX) can effectively neutralise components of PVR pathologic cascade. The purpose of this study was to determine the effectiveness of intravitreal methotrexate during surgical repair of rhegmatogenous retinal detachment. Subjects and Methods: Prospective, randomized, comparative, and interventional study. Setting: Research Institute of Ophthalmology and Al Azhar hospitals.The study included 30 eyes assigned into two groups. In Group A, 15 patients received intravitreal methotrexate injections. Group B, 15 patients had PPV without intravitreal methotrexate injection.Patients were subjected to a complete preoperative ophthalmic examination. Group A, during surgery, received Methotrexate in a dose o of 250 microgram / 0.1 ml infusion. Patients were examined during the first day, one week, one month, and three months follow-up visits. Results: The study comparing the two groups revealed a significant increase in IOP (1 week) and a significant decrease in BCVA (one week) in the MTX group (p < 0.05). Also, there was significantly decreased in postoperative BCVA in the control group (p < 0.01). However, (the MTX group) showed a significant increase in postoperative IOP (p < 0.05) and a significant decrease in postoperative BCVA (p < 0.01). Conclusion: Our research demonstrated the safety of intravitreal methotrexate injection in eyes with PVR and RRD, but it had no effect on the progression of PVR or the anatomical status up to three months following PPV. | ||||
| Keywords | ||||
| Methotrexate intravitreal; rhegmatogenous retinal detachment; Proliferative Vitreoretinopathy | ||||
|
Statistics Article View: 14 |
||||
